2023 World Conference on Lung Cancer (Posters)-P2.01. Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT

P2.01. Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the initial results of a phase 1 study on the use of 89Zr-durvalumab PET/CT to assess the expression of PD-L1 in stage III non-small cell lung cancer (NSCLC) patients undergoing concurrent chemo-radiotherapy. The study aims to investigate the feasibility of using this imaging technique as a potential biomarker for monitoring PD-L1 expression during treatment. <br /><br />The study enrolled patients with stage III NSCLC who were eligible for curative-intent concurrent chemoradiotherapy. Patients underwent 89Zr-durvalumab and FDG PET/CT scans before, during, and after radiotherapy treatment. Liquid biopsy and sequential EBUS sampling were also performed before and after radiotherapy treatment in selected patients.<br /><br />The first patient analyzed in this presentation was a 64-year-old male with stage 3C NSCLC, exon 21 (L858) EGFR mutation, and PD-L1 expression of 90%. The 89Zr-durvalumab PET/CT scans showed a decrease in avidity after 14 days of radiotherapy, indicating a potential reduction in tumor volume. The maximum diameter of the right paratracheal node and the right supraclavicular fossa node also decreased. The results of the 6 weeks post-radiotherapy scan are still pending.<br /><br />The authors conclude that 89Zr-durvalumab PET/CT can be used to monitor PD-L1 expression during radiotherapy treatment. However, further investigations are needed to correlate these findings with PD-L1 immunohistochemistry and validate the use of this imaging technique as a potential biomarker. This study provides insights into the potential of utilizing immunoPET in the characterization and monitoring of PD-L1 expression in locally advanced lung cancer patients undergoing radiotherapy.

Asset Subtitle

Fiona Hegi-Johnson

Meta Tag

Speaker Fiona Hegi-Johnson

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

89Zr-durvalumab PET/CT

PD-L1 expression

stage III non-small cell lung cancer

chemo-radiotherapy

biomarker

treatment monitoring

liquid biopsy

sequential EBUS sampling

EGFR mutation

immunoPET